<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Hyperphosphatemia • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Hyperphosphatemia • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/hyperphosphatemia/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/hyperphosphatemia/" />

<link rel="stylesheet" href="/wiki/style.css" />

  </head>
  <body>
    <div
      class="fixed top-0 w-screen px-4 py-4 md:px-10 bg-slate-200 bg-opacity-90"
    >
    <div class="flex items-center justify-between max-w-6xl mx-auto">
      <a href="/wiki/" title="Home">
        <img src="/wiki/assets/avatar.png" class="w-10 h-10 " />
      </a>

      <nav class="flex space-x-2 uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-slate-600 hover:text-slate-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 rounded hover:bg-slate-600 hover:text-slate-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>
    <div class="mx-auto">

    <div class="flex items-center justify-center max-w-full px-6 mt-32 mb-32">
      <div  class="prose"><h1>hyperphosphatemia</h1>
<ul>
<li>related: <a href="/wiki/notes/Nephrology/">Nephrology</a>, <a href="/wiki/notes/when%20to%20start%20sevelamer/">when to start sevelamer</a></li>
<li>tags: #nephrology</li>
</ul>
<hr>
<h2>Phosphate binders</h2>
<ul>
<li><a href="https://www.kidney-international.org/article/S0085-2538(15)50372-4/pdf">source</a></li>
</ul>
<p>Dietary restriction of phosphorus, although important,
is difficult to accomplish because dialysis patients are encouraged to consume a relatively <mark>[[high protein diet]]</mark> in
order to prevent protein malnutrition. Similarly, <mark>intermittent hemodialysis alone does not adequately control serum phosphorus in most patients</mark>. However, the use of more frequent dialysis such as <mark>short daily dialysis</mark> or long nocturnal hemodialysis may be effective in achieving the recommended goal serum phosphorus level without the use of phosphate binders. Unfortunately, these dialysis modalities are still in the experimental stage, and have not yet been widely applied in clinical practice. Consequently, phosphate binders are routinely prescribed for most patients with end-stage renal disease (ESRD) in order to reduce intestinal absorption of dietary phosphorus and prevent hyperphosphatemia.</p>
<p>The ideal phosphate binder should bind most dietary phosphate in the intestine without producing significant adverse effects. It should also be relatively inexpensive, because most dialysis patients usually consume relatively large daily doses of the binder. Unfortunately, none of the currently used phosphate binders fulfill all these requirements. This is best exemplified by <mark>aluminum hydroxide</mark>, which is probably the most cost-effective phosphate binder but has largely been abandoned because of the risks of <mark>aluminum intoxication</mark> with encephalopathy and osteomalacia. As a result, <mark>calcium acetate and calcium carbonate</mark> replaced aluminum hydroxide as the most widely prescribed phosphate binders.</p>
<pre><code class="language-ad-note">If use aluminum hydroxide, give 2 doses. Stop sevelamer
</code></pre>
<p>However, recent concern over the possible risks of calcium loading from these binders has led to introduction of the considerably more expensive non-calcium, non-aluminum phosphate binder, <mark>sevelamer hydrochloride</mark>.</p>
<p>In clinical practice, calcium acetate and sevelamer hydrochloride are currently the two most commonly used phosphate binders. Previous studies comparing these two binders suggested that they are equally effective in controlling serum phosphorus. Unfortunately, previous trials did not allow for adequate comparison of these binders because by design they were either open-label, single-arm titration, or placebo-controlled. Moreover, in most of these studies, sevelamer hydrochloride was not usually effective in controlling serum phosphorus to the recommended goal of 5.5 mg/dL or less. Given the enormous financial burden of caring for the ever-increasing dialysis population in the United States, it is imperative that the newer and more expensive therapy be shown to be at least equally efficacious in achieving the desired goals for serum phosphorus before recommending it for widespread use in patients with chronic kidney disease (CKD) on maintenance hemodialysis.</p>
<ul>
<li><a href="/wiki/notes/CARE%20study/">CARE study</a></li>
</ul>
<h2>Renvela</h2>
<ul>
<li>Stop when phos &gt; 5.5</li>
<li>Can stop when phos &lt; 5</li>
<li>Start with 800 TID</li>
<li>Can go up to 2400 TID, after which consider dialysis or aluminum hydroxide</li>
<li>Can also start when Ca-phos product  &gt; 40?</li>
</ul>
</div>
      
    </div>

    <div class="max-w-4xl mx-auto prose">
                  <hr />
<p>Backlinks</p>


<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Nephrology/" class="peer">Nephrology</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>Nephrology</h1>
<hr>
<ul>
<li>Keywords:: <a href="/wiki/notes/Step%203/">Step 3</a>, <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<hr>
<h2>To learns</h2>
<ul>
<li>ANCA vasculitis</li>
<li>[ ] stones: citrate and calcium physiology</li>
</ul>
<h2>Physiology</h2>
<ul>
<li><a href="/wiki/notes/normal%20renal%20function/">normal renal function</a></li>
<li><a href="/wiki/notes/urinalysis/">urinalysis</a></li>
<li><a href="/wiki/notes/IV%20fluids/">IV fluids</a></li>
</ul>
<h2>To organize</h2>
<ul>
<li><a href="/wiki/notes/Hypertension/">Hypertension</a></li>
<li><a href="/wiki/notes/lithium/">lithium</a></li>
<li><a href="/wiki/notes/parathyroid%20disease/">parathyroid disease</a></li>
<li><a href="/wiki/notes/ADPKD/">ADPKD</a></li>
<li><a href="/wiki/notes/RTA/">RTA</a></li>
<li><a href="/wiki/notes/hematuria/">hematuria</a></li>
</ul>
<h2>electrolytes</h2>
<ul>
<li><a href="/wiki/notes/BUN%20elevation/">BUN elevation</a></li>
<li><a href="/wiki/notes/hyperphosphatemia/">hyperphosphatemia</a></li>
<li><a href="/wiki/notes/hypocalcemia/">hypocalcemia</a></li>
<li><a href="/wiki/notes/hypercalcemia/">hypercalcemia</a></li>
<li><a href="/wiki/notes/calciphylaxis/">calciphylaxis</a></li>
</ul>
<h2>Acid baseline</h2>
<ul>
<li>[[anion</li>
</ul>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/when to start sevelamer/" class="peer">When to Start Sevelamer</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>when to start sevelamer</h1>
<ul>
<li>related: <a href="/wiki/notes/Nephrology/">Nephrology</a>, <a href="/wiki/notes/hyperphosphatemia/">hyperphosphatemia</a></li>
<li>tags: #note</li>
</ul>
<hr>
<ul>
<li>Correct Ca x phosphorus &gt; 55</li>
</ul>
<p>Hyperphosphatemia has been clearly shown to play a major role in the pathogenesis of secondary hyper-parathyroidism, extraosseous calcification, and increased mortality risk in hemodialysis patients. Serum phosphorus exceeding <mark>5.5 mg/dL</mark> and calcium phosphate product (Ca × P) over <mark>52 mg2/dL2</mark> each correlate with increased mortality risk in dial</p>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/CARE study/" class="peer">CARE Study</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>CARE study</h1>
<ul>
<li>related: <a href="/wiki/notes/Nephrology/">Nephrology</a>, <a href="/wiki/notes/hyperphosphatemia/">hyperphosphatemia</a>, <a href="/wiki/notes/when%20to%20start%20sevelamer/">when to start sevelamer</a></li>
<li>tags: #note</li>
</ul>
<hr>
<p>CARE study: <a href="https://www.kidney-international.org/article/S0085-2538(15)50372-4/pdf">https://www.kidney-international.org/article/S0085-2538(15)50372-4/pdf</a></p>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-4xl mb-10 text-sm text-center mt-96 ">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
